Virtually all patients with multiple myeloma become unresponsive to treatment with
proteasome inhibitors over time. Relapsed/refractory multiple myeloma is accompanied by …

Multiple myeloma (MM) results from malignancy in plasma cells and occurs at ages> 50
years. MM is the second most common hematologic malignancy after non-Hodgkin …

The upgraded knowledge of tumor biology and microenviroment provides information on
differences in neoplastic and normal cells. Thus, the need to target these differences led to …

The prognosis of patients with multiple myeloma (MM) has improved dramatically with the
introduction of new therapeutic drugs, but the disease eventually becomes drug-resistant …

Multiple myeloma (MM) is an incurable blood cancer that is often characterized by
amplification and overexpression of the MYC oncogene. Despite efforts, direct targeting of …

Osteolytic bone lesions are one of the central features of multiple myeloma (MM) and lead to
bone pain, fractures, decreased quality of life, and decreased survival. Dysfunction of the …

Multiple myeloma with clonal plasma expansion in bone marrow is the second most
common hematologic malignancy in the world. Though the improvement of outcomes from …

Multiple myeloma (MM) causes approximately 20% of deaths from blood cancers.
Notwithstanding significant therapeutic progress, such as with proteasome inhibitors (PIs) …

YM155, a novel small molecule inhibitor of survivin, shows broad anticancer activity. Here,
we have focused on the cytotoxic activity of YM155 against multiple myeloma (MM) including …

Szpiczak mnogi to złośliwy nowotwór wywodzący się z komórek B znajdujących się w
końcowym etapie różnicowania. Choroba charakteryzuje się podwyższonymi poziomami …